The Ophthalmic Drugs Market Report 2024-2034: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.
The global ophthalmic drugs market is experiencing substantial growth, and this can be attributed to several key factors. The increasing prevalence of ophthalmic disorders, including conditions like glaucoma, macular degeneration, diabetic retinopathy, and dry eye syndrome, is driving the demand for more effective pharmaceutical treatments. As the world’s population ages and lifestyles evolve, the incidence of these eye-related disorders continues to rise, creating a sustained need for innovative drugs to address them.
The presence of a robust emerging pipeline of drugs is contributing significantly to market growth. Pharmaceutical companies are actively investing in research and development efforts to develop new and improved ophthalmic medications. These pipeline drugs hold the promise of enhanced therapeutic options and more targeted treatments, further fueling the market’s expansion. Together, these factors underscore the dynamic and evolving nature of the global ophthalmic drugs market, which is poised for continued growth in the foreseeable future.
Side Effects of Drugs Likely to Challenge Industry Growth
The utilization of topical drugs can result in various side effects, encompassing temporary vision cloudiness, allergic responses, visual disruptions, and sensations of stinging, burning, or itching. Additionally, more infrequent side effects encompass sudden alterations in vision, severe headaches, tunnel vision, eye discomfort, pain behind the eyes, and indications of potential new eye infections, such as swelling and drainage. Consequently, the presence of these side effects linked to topical steroidal drugs has the potential to impede market growth.
The challenge posed to the ophthalmic drugs market in developing nations by drug side effects is a complex issue. Resolving this concern demands a holistic approach that encompasses various measures, such as enhancing healthcare accessibility, improving medical infrastructure, fostering patient education, countering counterfeit drug proliferation, and establishing stringent regulatory frameworks to uphold the safety and effectiveness of ophthalmic medications.
What Questions Should You Ask before Buying a Market Research Report?
• How is the ophthalmic drugs market evolving?
• What is driving and restraining the ophthalmic drugs market?
• How will each ophthalmic drugs submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2034?
• How will the market shares for each ophthalmic drugs submarket develop from 2024 to 2034?
• What will be the main driver for the overall market from 2024 to 2034?
• Will leading ophthalmic drugs markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
• How will the market shares of the national markets change by 2034 and which geographical region will lead the market in 2034?
• Who are the leading players and what are their prospects over the forecast period?
• How will the industry evolve during the period between 2024 and 2034? What are the implications of ophthalmic drugs projects taking place now and over the next 10 years?
• Is there a greater need for product commercialisation to further scale the ophthalmic drugs market?
• Where is the ophthalmic drugs market heading and how can you ensure you are at the forefront of the market?
• What are the best investment options for new product and service lines?
• What are the key prospects for moving companies into a new growth path and C-suite?
You need to discover how this will impact the Ophthalmic Drugs Market today, and over the next 10 years:
• Our 284-page report provides 125 tables, 168 charts/graphs exclusively to you.
• The report highlights key lucrative areas in the industry so you can target them – NOW.
• It contains in-depth analysis of global, regional and national sales and growth.
• It highlights for you the key successful trends, changes and revenue projections made by your competitors.
This report tells you TODAY how the Ophthalmic Drugs Market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.
Forecasts to 2034 and other analyses reveal commercial prospects
• In addition to revenue forecasting to 2034, our new study provides you with recent results, growth rates, and market shares.
• You will find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising ophthalmic drugs prices and recent developments.
This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, “V”, “L”, “W” and “U” are discussed in this report.
Segments Covered in the Report
Type
• Prescription Drugs
• OTC Drugs
Indication
• Retinal Disorders
• Infection/Inflammation/Allergy
• Glaucoma
• Dry Eye
Route of Administration
• Topical
• Parenteral
Distribution Channel
• Hospital Pharmacies
• Drug Stores
• Online Pharmacies
In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 26 leading national markets:
North America
• U.S.
• Canada
Europe
• Germany
• Spain
• UK
• France
• Italy
• Netherlands
• Switzerland
• Rest of Europe
Asia Pacific
• China
• Japan
• India
• Australia
• South Korea
• Malaysia
• Singapore
• Rest of Asia Pacific
Latin America
• Brazil
• Argentina
• Mexico
• Chile
• Rest of Latin America
MEA
• GCC
• South Africa
• Rest of MEA
Need industry data? Please contact us today.
The report also includes profiles and for some of the leading companies in the Ophthalmic Drugs Market, 2024 to 2034, with a focus on this segment of these companies’ operations.
Leading companies and the potential for market growth
• AbbVie Inc.
• Alimera Sciences
• Apellis Pharmaceuticals
• Bausch & Lomb Incorporated
• Bayer AG
• Breye Therapeutics ApS
• EyeBio
• F. Hoffmann-La Roche Ltd.
• Johnson & Johnson Services Inc.
• Novaliq GmbH
• Novartis AG
• Pfizer Inc.
• Regeneron Pharmaceuticals Inc.
• Santen Pharmaceutical Co., Ltd.
• SpliceBio
• Teva Pharmaceutical Industries Ltd.
Overall world revenue for ophthalmic drugs market, 2024 to 2034 in terms of value the market will surpass US$32.0 billion in 2024, our work calculates. We predict strong revenue growth through to 2034. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
How will the Ophthalmic Drugs Market, 2024 to 2034 report help you?
In summary, our 280+ page report provides you with the following knowledge:
• Revenue forecasts to 2034 for Ophthalmic Drugs Market, 2024 to 2034 Market, with forecasts for type, distribution channel, indication, route of administration, each forecast at a global and regional level – discover the industry’s prospects, finding the most lucrative places for investments and revenues.
• Revenue forecasts to 2034 for five regional and 26 key national markets – See forecasts for the Ophthalmic Drugs Market, 2024 to 2034 market in North America, Europe, Asia-Pacific, Latin America and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.
• Prospects for established firms and those seeking to enter the market – including company profiles for 16 of the major companies involved in the Ophthalmic Drugs Market, 2024 to 2034.
Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.
Information found nowhere else
With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain’s study is for everybody needing commercial analyses for the Ophthalmic Drugs Market, 2024 to 2034, market-leading companies. You will find data, trends and predictions.
To access the data contained in this document please email contactus@visiongain.com
Buy our report today Ophthalmic Drugs Market Report 2024-2034: Forecasts by Type (Prescription Drugs, OTC Drugs), by Indication (Retinal Disorders, Infection/Inflammation/Allergy, Glaucoma, Dry Eye), by Route of Administration (Topical, Parenteral), by Distribution Channel (Hospital Pharmacies, Drug Stores, Online Pharmacies) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Companies AND COVID-19 Impact and Recovery Pattern Analysis. Avoid missing out by staying informed – order our report now.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
Do you have any custom requirements we can help you with? Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: contactus@visiongain.com
1 Report Overview
1.1 Objectives of the Study
1.2 Introduction to Ophthalmic Drugs Market
1.3 What This Report Delivers
1.4 Why You Should Read This Report
1.5 Key Questions Answered by This Analytical Report
1.6 Who is This Report for?
1.7 Methodology
1.7.1 Market Definitions
1.7.2 Market Evaluation & Forecasting Methodology
1.7.3 Data Validation
1.7.3.1 Primary Research
1.7.3.2 Secondary Research
1.8 Frequently Asked Questions (FAQs)
1.9 Associated Visiongain Reports
1.10 About Visiongain
2 Executive Summary
3 Market Overview
3.1 Key Findings
3.2 Market Dynamics
3.2.1 Market Driving Factors
3.2.1.1 Rising Frequency and Occurrence of Eye-related Conditions
3.2.1.2 Increasing Prevalence of Diabetes
3.2.1.3 Presence of Strong Emerging Pipeline Drugs
3.2.2 Market Restraining Factors
3.2.2.1 Lack of Health Insurance in the Developing Countries
3.2.2.2 Lack of Awareness Regarding the Available Treatment Options
3.2.2.3 Side Effects of Drugs
3.2.2.4 Patent Expiry of Blockbuster Drugs
3.2.3 Market Opportunities
3.2.3.1 Rise in Investment in Research and Development
3.2.3.2 Rise in Geriatric Population
3.3 COVID-19 Impact Analysis
3.4 Porter’s Five Forces Analysis
3.4.1 Bargaining Power of Suppliers
3.4.2 Bargaining Power of Buyers
3.4.3 Competitive Rivalry
3.4.4 Threat from Substitutes
3.4.5 Threat of New Entrants
3.5 PEST Analysis
3.5.1 Political
3.5.2 Economical
3.5.3 Social
3.5.4 Technological
4 Ophthalmic Drugs Market Analysis by Type
4.1 Key Findings
4.2 Type Segment: Market Attractiveness Index
4.3 Ophthalmic Drugs Market Size Estimation and Forecast by Type
4.4 Prescription Drugs
4.4.1 Market Size by Region, 2024-2034 (US$ Billion)
4.4.2 Market Share by Region, 2024 & 2034 (%)
4.5 OTC Drugs
4.5.1 Market Size by Region, 2024-2034 (US$ Billion)
4.5.2 Market Share by Region, 2024 & 2034 (%)
5 Ophthalmic Drugs Market Analysis by Distribution Channel
5.1 Key Findings
5.2 Distribution Channel Segment: Market Attractiveness Index
5.3 Ophthalmic Drugs Market Size Estimation and Forecast by Distribution Channel
5.4 Hospital Pharmacies
5.4.1 Market Size by Region, 2024-2034 (US$ Billion)
5.4.2 Market Share by Region, 2024 & 2034 (%)
5.5 Drug Stores
5.5.1 Market Size by Region, 2024-2034 (US$ Billion)
5.5.2 Market Share by Region, 2024 & 2034 (%)
5.6 Online Pharmacies
5.6.1 Market Size by Region, 2024-2034 (US$ Billion)
5.6.2 Market Share by Region, 2024 & 2034 (%)
6 Ophthalmic Drugs Market Analysis by Indication
6.1 Key Findings
6.2 Indication Segment: Market Attractiveness Index
6.3 Ophthalmic Drugs Market Size Estimation and Forecast by Indications
6.4 Retinal Disorders
6.4.1 Market Size by Region, 2024-2034 (US$ Billion)
6.4.2 Market Share by Region, 2024 & 2034 (%)
6.4.3 Retinal Disorders Market Size by Drugs, 2024-2034 (US$ Billion)
6.5 Infection/Inflammation/Allergy
6.5.1 Market Size by Region, 2024-2034 (US$ Billion)
6.5.2 Market Share by Region, 2024 & 2034 (%)
6.5.3 Infection/Inflammation/Allergy Market Size by Drugs, 2024-2034 (US$ Billion)
6.6 Dry Eye
6.6.1 Market Size by Region, 2024-2034 (US$ Billion)
6.6.2 Market Share by Region, 2024 & 2034 (%)
6.6.3 Dry Eye Market Size by Drugs, 2024-2034 (US$ Billion)
6.7 Glaucoma
6.7.1 Market Size by Region, 2024-2034 (US$ Billion)
6.7.2 Market Share by Region, 2024 & 2034 (%)
6.7.3 Glaucoma Market Size by Drugs, 2024-2034 (US$ Billion)
7 Ophthalmic Drugs Market Analysis by Route of Administration
7.1 Key Findings
7.2 Route of Administration Segment: Market Attractiveness Index
7.3 Ophthalmic Drugs Market Size Estimation and Forecast by Route of Administration
7.4 Topical
7.4.1 Market Size by Region, 2024-2034 (US$ Billion)
7.4.2 Market Share by Region, 2024 & 2034 (%)
7.5 Parenteral
7.5.1 Market Size by Region, 2024-2034 (US$ Billion)
7.5.2 Market Share by Region, 2024 & 2034 (%)
8 Ophthalmic Drugs Market Analysis by Region
8.1 Key Findings
8.2 Regional Market Size Estimation and Forecast
9 North America Ophthalmic Drugs Market Analysis
9.1 Key Findings
9.2 North America Ophthalmic Drugs Market Attractiveness Index
9.3 North America Ophthalmic Drugs Market by Country, 2024, 2029 & 2034 (US$ Billion)
9.4 North America Ophthalmic Drugs Market Size Estimation and Forecast by Country
9.5 North America Ophthalmic Drugs Market Size Estimation and Forecast by Type
9.6 North America Ophthalmic Drugs Market Size Estimation and Forecast by Distribution channel
9.7 North America Ophthalmic Drugs Market Size Estimation and Forecast by Indications
9.8 North America Ophthalmic Drugs Market Size Estimation and Forecast by Route of Administration
9.9 U.S. Ophthalmic Drugs Market Analysis
9.10 Canada Ophthalmic Drugs Market Analysis
10 Europe Ophthalmic Drugs Market Analysis
10.1 Key Findings
10.2 Europe Ophthalmic Drugs Market Attractiveness Index
10.3 Europe Ophthalmic Drugs Market by Country, 2024, 2029 & 2034 (US$ Billion)
10.4 Europe Ophthalmic Drugs Market Size Estimation and Forecast by Country
10.5 Europe Ophthalmic Drugs Market Size Estimation and Forecast by Type
10.6 Europe Ophthalmic Drugs Market Size Estimation and Forecast by Distribution Channel
10.7 Europe Ophthalmic Drugs Market Size Estimation and Forecast by Indications
10.8 Europe Ophthalmic Drugs Market Size Estimation and Forecast by Route of Administration
10.9 Germany Ophthalmic Drugs Market Analysis
10.10 France Ophthalmic Drugs Market Analysis
10.11 UK Ophthalmic Drugs Market Analysis
10.12 Italy Ophthalmic Drugs Market Analysis
10.13 Spain Ophthalmic Drugs Market Analysis
10.14 Netherlands Ophthalmic Drugs Market Analysis
10.15 Switzerland Ophthalmic Drugs Market Analysis
10.16 Rest of Europe Ophthalmic Drugs Market Analysis
11 Asia Pacific Ophthalmic Drugs Market Analysis
11.1 Key Findings
11.2 Asia Pacific Ophthalmic Drugs Market Attractiveness Index
11.3 Asia Pacific Ophthalmic Drugs Market by Country, 2024, 2029 & 2034 (US$ Billion)
11.4 Asia Pacific Ophthalmic Drugs Market Size Estimation and Forecast by Country
11.5 Asia Pacific Ophthalmic Drugs Market Size Estimation and Forecast by Type
11.6 Asia Pacific Ophthalmic Drugs Market Size Estimation and Forecast by Distribution Channel
11.7 Asia Pacific Ophthalmic Drugs Market Size Estimation and Forecast by Indications
11.8 Asia Pacific Ophthalmic Drugs Market Size Estimation and Forecast by Route of Administration
11.9 Japan Ophthalmic Drugs Market Analysis
11.10 China Ophthalmic Drugs Market Analysis
11.11 India Ophthalmic Drugs Market Analysis
11.12 Australia Ophthalmic Drugs Market Analysis
11.13 South Korea Ophthalmic Drugs Market Analysis
11.14 Malaysia Ophthalmic Drugs Market Analysis
11.15 Singapore Ophthalmic Drugs Market Analysis
11.16 Rest of Asia Pacific Ophthalmic Drugs Market Analysis
12 Latin America Ophthalmic Drugs Market Analysis
12.1 Key Findings
12.2 Latin America Ophthalmic Drugs Market Attractiveness Index
12.3 Latin America Ophthalmic Drugs Market by Country, 2024, 2029 & 2034 (US$ Billion)
12.4 Latin America Ophthalmic Drugs Market Size Estimation and Forecast by Country
12.5 Latin America Ophthalmic Drugs Market Size Estimation and Forecast by Type
12.6 Latin America Ophthalmic Drugs Market Size Estimation and Forecast by Distribution Channel
12.7 Latin America Ophthalmic Drugs Market Size Estimation and Forecast by Indications
12.8 Latin America Ophthalmic Drugs Market Size Estimation and Forecast by Route of Administration
12.9 Brazil Ophthalmic Drugs Market Analysis
12.10 Argentina Ophthalmic Drugs Market Analysis
12.11 Mexico Ophthalmic Drugs Market Analysis
12.12 Chile Ophthalmic Drugs Market Analysis
12.13 Rest of Latin America Ophthalmic Drugs Market Analysis
13 MEA Ophthalmic Drugs Market Analysis
13.1 Key Findings
13.2 MEA Ophthalmic Drugs Market Attractiveness Index
13.3 MEA Ophthalmic Drugs Market by Country, 2024, 2029 & 2034 (US$ Billion)
13.4 MEA Ophthalmic Drugs Market Size Estimation and Forecast by Country
13.5 MEA Ophthalmic Drugs Market Size Estimation and Forecast by Type
13.6 MEA Ophthalmic Drugs Market Size Estimation and Forecast by Distribution Channel
13.7 MEA Ophthalmic Drugs Market Size Estimation and Forecast by Indications
13.8 MEA Ophthalmic Drugs Market Size Estimation and Forecast by Route of Administration
13.9 GCC Ophthalmic Drugs Market Analysis
13.10 South Africa Ophthalmic Drugs Market Analysis
13.11 Rest of MEA Ophthalmic Drugs Market Analysis
14 Company Profiles
14.1 Competitive Landscape, 2023
14.2 Strategic Outlook
14.3 Novartis AG
14.3.1 Company Snapshot
14.3.2 Company Overview
14.3.3 Financial Analysis
14.3.3.1 Net Revenue, 2018-2022
14.3.3.2 Regional Market Shares, 2022
14.3.3.3 R&D Expense, 2018-2022
14.3.4 Product Offered
14.3.5 Strategic Outlook
14.4 Bayer AG
14.4.1 Company Snapshot
14.4.2 Company Overview
14.4.3 Financial Analysis
14.4.3.1 Net Revenue, 2018-2022
14.4.3.2 Regional Market Shares, 2022
14.4.3.3 R&D Expense, 2018-2022
14.4.4 Product Benchmarking
14.4.5 Strategic Outlook
14.5 Pfizer Inc.
14.5.1 Company Snapshot
14.5.2 Company Overview
14.5.3 Financial Analysis
14.5.3.1 Revenue, 2018-2022
14.5.3.2 Regional Market Shares, 2022
14.5.3.3 R&D Expense, 2018-2022
14.5.4 Product Benchmarking
14.6 Bausch & Lomb Incorporated
14.6.1 Company Snapshot
14.6.2 Company Overview
14.6.3 Financial Analysis
14.6.3.1 Revenue, 2018-2022
14.6.3.2 R&D Expense, 2018-2022
14.6.4 Product Benchmarking
14.6.5 Strategic Outlook
14.7 Santen Pharmaceutical Co., Ltd.
14.7.1 Company Snapshot
14.7.2 Company Overview
14.7.3 Financial Analysis
14.7.3.1 Revenue, 2018-2022
14.7.3.2 R&D Expense, 2018-2022
14.7.4 Product Benchmarking
14.7.5 Strategic Outlook
14.8 Johnson & Johnson Services Inc.
14.8.1 Company Snapshot
14.8.2 Company Overview
14.8.3 Financial Analysis
14.8.3.1 Revenue, 2018-2022
14.8.3.2 Regional Market Shares, 2022
14.8.3.3 R&D Expense, 2018-2022
14.8.4 Product Benchmarking
14.8.5 Strategic Outlook
14.9 Regeneron Pharmaceuticals Inc.
14.9.1 Company Snapshot
14.9.2 Company Overview
14.9.3 Financial Analysis
14.9.3.1 Revenue, 2018-2022
14.9.3.2 R&D Expense, 2018-2022
14.9.4 Product Benchmarking
14.9.5 Strategic Outlook
14.10 AbbVie Inc.
14.10.1 Company Snapshot
14.10.2 Company Overview
14.10.3 Financial Analysis
14.10.3.1 Revenue, 2018-2022
14.10.3.2 Regional Market Shares, 2022
14.10.3.3 R&D Expense, 2018-2022
14.10.4 Product Benchmarking
14.10.5 Strategic Outlook
14.11 F. Hoffmann-La Roche Ltd
14.11.1 Company Snapshot
14.11.2 Company Overview
14.11.3 Financial Analysis
14.11.3.1 Revenue, 2018-2022
14.11.3.2 Regional Market Shares, 2022
14.11.3.3 R&D Expense, 2018-2022
14.11.4 Product Benchmarking
14.11.5 Strategic Outlook
14.12 Teva Pharmaceutical Industries Ltd.
14.12.1 Company Snapshot
14.12.2 Company Overview
14.12.3 Financial Analysis
14.12.3.1 Revenue, 2018-2022
14.12.3.2 Regional Market Shares, 2022
14.12.3.3 R&D Expense, 2018-2022
14.12.4 Product Benchmarking
14.12.5 Strategic Outlook
14.13 Apellis Pharmaceuticals
14.13.1 Company Snapshot
14.13.2 Company Overview
14.13.3 Financial Analysis
14.13.3.1 Revenue, 2018-2022
14.13.3.2 R&D Expense, 2018-2022
14.13.4 Product Benchmarking
14.13.5 Strategic Outlook
14.14 Novaliq GmbH
14.14.1 Company Snapshot
14.14.2 Company Overview
14.14.3 Product Benchmarking
14.14.4 Strategic Outlook
14.15 Alimera Sciences
14.15.1 Company Snapshot
14.15.2 Company Overview
14.15.3 Financial Analysis
14.15.3.1 Revenue, 2018-2022
14.15.3.2 R&D Expense, 2018-2022
14.15.4 Product Benchmarking
14.15.5 Strategic Outlook
14.16 EyeBio
14.16.1 Company Snapshot
14.16.2 Company Overview
14.16.3 Product Benchmarking
14.16.4 Strategic Outlook
14.17 SpliceBio
14.17.1 Company Snapshot
14.17.2 Company Overview
14.17.3 Product Benchmarking
14.17.4 Strategic Outlook
14.18 Breye Therapeutics ApS
14.18.1 Company Snapshot
14.18.2 Company Overview
14.18.3 Product Benchmarking
14.18.4 Strategic Outlook
15 Conclusion and Recommendations
15.1 Concluding Remarks from Visiongain
15.2 Recommendations for Market Players
List of Tables
Table 1 Ophthalmic Drugs Market Snapshot, 2024 & 2034 (US$ billion, CAGR %)
Table 2 Ophthalmic Drugs Market, Product Pipeline
Table 3 Ophthalmic Drugs Contract Manufacturing Market Forecast by Region 2024-2034 (US$ Billion, AGR%, CAGR%): "V" Shaped Recovery
Table 4 Ophthalmic Drugs Contract Manufacturing Market Forecast by Region 2024-2034 (US$ Billion, AGR%, CAGR%): "U" Shaped Recovery
Table 5 Ophthalmic Drugs Contract Manufacturing Market Forecast by Region 2024-2034 (US$ Billion, AGR%, CAGR%): "W" Shaped Recovery
Table 6 Ophthalmic Drugs Contract Manufacturing Market Forecast by Region 2024-2034 (US$ Billion, AGR%, CAGR%): "L" Shaped Recovery
Table 7 Ophthalmic Drugs Market Forecast by Type, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 8 Prescription Drugs Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 9 OTC Drugs Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 10 Ophthalmic Drugs Market Forecast by Distribution Channel, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 11 Hospital Pharmacies Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 12 Drug Stores Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 13 Online Pharmacies Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 14 Ophthalmic Drugs Market Forecast by Indications, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 15 Retinal Disorders Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 16 Retinal Disorders in Ophthalmic Drugs Market Forecast by Indications, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 17 Infection/Inflammation/Allergy Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 18 Infection/Inflammation/Allergy in Ophthalmic Drugs Market Forecast by Indications, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 19 Dry Eye Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 20 Dry Eye in Ophthalmic Drugs Market Forecast by Indications, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 21 Glaucoma Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 22 Glaucoma in Ophthalmic Drugs Market Forecast by Indications, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 23 Ophthalmic Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 24 Topical Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 25 Parenteral Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 26 Ophthalmic Drugs Market Forecast by Region 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 27 North America Ophthalmic Drugs Market Forecast by Country, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 28 North America Ophthalmic Drugs Market Forecast by Type, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 29 North America Ophthalmic Drugs Market Forecast by Distribution Channel, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 30 North America Ophthalmic Drugs Market Forecast by Indications, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 31 North America Ophthalmic Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 32 U.S. Ophthalmic Drugs Market Forecast by Country, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 33 Canada Ophthalmic Drugs Market Forecast by Country, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 34 Europe Ophthalmic Drugs Market Forecast by Country, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 35 Europe Ophthalmic Drugs Market Forecast by Type, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 36 Europe Ophthalmic Drugs Market Forecast by Distribution Channel, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 37 Europe Ophthalmic Drugs Market Forecast by Indications, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 38 Europe Ophthalmic Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 39 Germany Ophthalmic Drugs Market Forecast by Country, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 40 France Ophthalmic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 41 UK Ophthalmic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 42 Italy Ophthalmic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 43 Spain Ophthalmic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 44 Netherlands Ophthalmic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 45 Switzerland Ophthalmic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 46 Rest of Europe Ophthalmic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 47 Asia Pacific Ophthalmic Drugs Market Forecast by Country, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 48 Asia Pacific Ophthalmic Drugs Market Forecast by Type, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 49 Asia Pacific Ophthalmic Drugs Market Forecast by Distribution Channel, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 50 Asia Pacific Ophthalmic Drugs Market Forecast by Indications, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 51 Asia Pacific Ophthalmic Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 52 Japan Ophthalmic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 53 China Ophthalmic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 54 India Ophthalmic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 55 Australia Ophthalmic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 56 South Korea Ophthalmic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 57 Malaysia Ophthalmic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 58 Singapore Ophthalmic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 59 Asia-Pacific Ophthalmic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 60 Latin America Ophthalmic Drugs Market Forecast by Country, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 61 Latin America Ophthalmic Drugs Market Forecast by Type, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 62 Latin America Ophthalmic Drugs Market Forecast by Distribution Channel, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 63 Latin America Ophthalmic Drugs Market Forecast by Indications, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 64 Latin America Ophthalmic Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 65 Brazil Ophthalmic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 66 Argentina Ophthalmic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 67 Mexico Ophthalmic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 68 Chile Ophthalmic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 69 Rest of Latin America Ophthalmic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 70 MEA Ophthalmic Drugs Market Forecast by Country, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 71 MEA Ophthalmic Drugs Market Forecast by Type, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 72 MEA Ophthalmic Drugs Market Forecast by Distribution Channel, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 73 MEA Ophthalmic Drugs Market Forecast by Indications, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 74 MEA Ophthalmic Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 75 GCC Ophthalmic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 76 South Africa Ophthalmic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 77 Rest of MEA Ophthalmic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 78 Strategic Outlook
Table 79 Novartis AG: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 80 Novartis AG: Product Benchmarking
Table 81 Novartis AG: Strategic Outlook
Table 82 Bayer AG: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 83 Bayer AG: Product Benchmarking
Table 84 Bayer AG: Strategic Outlook
Table 85 Pfizer Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 86 Pfizer Inc.: Product Benchmarking
Table 87 Bausch & Lomb Incorporated: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 88 Bausch & Lomb Incorporated: Product Benchmarking
Table 89 Bausch & Lomb Incorporated: Strategic Outlook
Table 90 Santen Pharmaceutical Co., Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 91 Santen Pharmaceutical Co., Ltd.: Product Benchmarking
Table 92 Santen Pharmaceutical Co., Ltd.: Strategic Outlook
Table 93 Johnson & Johnson Services Inc: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 94 Johnson & Johnson Private Limited: Product Benchmarking
Table 95 Johnson & Johnson Private Limited: Strategic Outlook
Table 96 Regeneron Pharmaceuticals Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 97 Regeneron Pharmaceuticals Inc.: Product Benchmarking
Table 98 Regeneron Pharmaceuticals Inc.: Strategic Outlook
Table 99 AbbVie Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 100 AbbVie Inc.: Product Benchmarking
Table 101 AbbVie Inc.: Strategic Outlook
Table 102 F. Hoffmann-La Roche Ltd: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 103 F. Hoffmann-La Roche Ltd: Product Benchmarking
Table 104 F. Hoffmann-La Roche Ltd: Strategic Outlook
Table 105 Teva Pharmaceutical Industries Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 106 Teva Pharmaceutical Industries Ltd.: Product Benchmarking
Table 107 Teva Pharmaceutical Industries Ltd.: Strategic Outlook
Table 108 Apellis Pharmaceuticals: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 109 Apellis Pharmaceuticals: Product Benchmarking
Table 110 Apellis Pharmaceuticals: Strategic Outlook
Table 111 Novaliq GmbH: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 112 Novaliq GmbH.: Product Benchmarking
Table 113 Novaliq GmbH: Strategic Outlook
Table 114 Alimera Sciences: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 115 Alimera Sciences: Product Benchmarking
Table 116 Alimera Sciences: Strategic Outlook
Table 117 EyeBio: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 118 EyeBio: Product Benchmarking
Table 119 EyeBio: Strategic Outlook
Table 120 SpliceBio: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 121 SpliceBio: Product Benchmarking
Table 122 SpliceBio: Strategic Outlook
Table 123 Breye Therapeutics ApS: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 124 Breye Therapeutics ApS: Product Benchmarking
Table 125 Breye Therapeutics ApS: Strategic Outlook
List of Figures
Figure 1 Ophthalmic Drugs Market Segmentation
Figure 2 Ophthalmic Drugs Market by Type: Market Attractiveness Index
Figure 3 Ophthalmic Drugs Market Forecast by Distribution Channel: Market Attractiveness Index
Figure 4 Ophthalmic Drugs Market Forecast by Indications: Market Attractiveness Index
Figure 5 Ophthalmic Drugs Market Forecast by Route of Administration: Market Attractiveness Index
Figure 6 Ophthalmic Drugs Market Attractiveness Index by Region
Figure 7 Ophthalmic Drugs Market: Market Dynamics
Figure 8 Ophthalmic Drugs Market by Region, 2024-2034 (US$ Billion, AGR (%), CAGR (%)): “V” Shaped Recovery
Figure 9 Ophthalmic Drugs Market by Region, 2024-2034 (US$ Billion, AGR (%), CAGR (%)): “U” Shaped Recovery
Figure 10 Ophthalmic Drugs Market by Region, 2024-2034 (US$ Billion, AGR (%), CAGR (%)): “W” Shaped Recovery
Figure 11 Ophthalmic Drugs Market by Region, 2024-2034 (US$ Billion, AGR (%), CAGR (%)): “L” Shaped Recovery
Figure 12 Ophthalmic Drugs Market: Porter’s Five Forces Analysis
Figure 13 Ophthalmic Drugs Market: PEST Analysis
Figure 14 Ophthalmic Drugs Market Forecast by Type: Market Attractiveness Index
Figure 15 Ophthalmic Drugs Market Forecast by Type, 2024-2034 (US$ Billion, AGR %)
Figure 16 Ophthalmic Drugs Market Share Forecast by Type, 2024, 2029, 2034 (%)
Figure 17 Prescription Drugs Market Forecast by Region, 2023 2034 (US$ Billion)
Figure 18 Prescription Drugs Market Share Forecast by Region, 2024 & 2034 (%)
Figure 19 OTC Drugs Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 20 OTC Drugs Market Share Forecast by Region, 2024 & 2034 (%)
Figure 21 Ophthalmic Drugs Market Forecast by Distribution Channel: Market Attractiveness Index
Figure 22 Ophthalmic Drugs Market Forecast By Distribution Channel, 2024-2034 (US$ Billion, AGR %)
Figure 23 Ophthalmic Drugs Market Share Forecast by Distribution Channel, 2024, 2029, 2034 (%)
Figure 24 Hospital Pharmacies Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 25 Hospital Pharmacies Market Share Forecast by Region, 2024 & 2034 (%)
Figure 26 Drug Stores Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 27 Drug Stores Market Share Forecast by Region, 2024 & 2034 (%)
Figure 28 Online Pharmacies Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 29 Online Pharmacies Market Share Forecast by Region, 2024 & 2034 (%)
Figure 30 Ophthalmic Drugs Market Forecast by Indication: Market Attractiveness Index
Figure 31 Ophthalmic Drugs Market Forecast By Indications, 2024-2034 (US$ Billion, AGR %)
Figure 32 Ophthalmic Drugs Market Share Forecast by Indications, 2024, 2029, 2034 (%)
Figure 33 Retinal Disorders Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 34 Retinal Disorders Market Share Forecast by Region, 2024 & 2034 (%)
Figure 35 Infection/Inflammation/Allergy Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 36 Infection/Inflammation/Allergy Market Share Forecast by Region, 2024 & 2034 (%)
Figure 37 Dry Eye Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 38 Dry Eye Market Share Forecast by Region, 2024 & 2034 (%)
Figure 39 Glaucoma Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 40 Glaucoma Market Share Forecast by Region, 2024 & 2034 (%)
Figure 41 Ophthalmic Drugs Market Forecast by Route of Administration: Market Attractiveness Index
Figure 42 Ophthalmic Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Billion, AGR %)
Figure 43 Ophthalmic Drugs Market Share Forecast by Route of administration, 2024, 2029, 2034 (%)
Figure 44 Topical Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 45 Topical Market Share Forecast by Region, 2024 & 2034 (%)
Figure 46 Parenteral Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 47 Parenteral Market Share Forecast by Region, 2024 & 2034 (%)
Figure 48 Ophthalmic Drugs Market Forecast by Region 2024 & 2034 (Revenue, CAGR%)
Figure 49 Ophthalmic Drugs Market Share Forecast by Region 2024, 2029, 2034(%)
Figure 50 Ophthalmic Drugs Market by Region, 2024-2034 (US$ Billion, AGR (%), CAGR (%))
Figure 51 North America Ophthalmic Drugs Market Attractiveness Index
Figure 52 North America Ophthalmic Drugs Market by Region, 2024, 2029 & 2034 (US$ Billion)
Figure 53 North America Ophthalmic Drugs Market Forecast by Country, 2024-2034 (US$ Billion, AGR %)
Figure 54 North America Ophthalmic Drugs Market Share Forecast by Country, 2024 & 2034 (%)
Figure 55 North America Ophthalmic Drugs Market Forecast by Type, 2024-2034 (US$ Billion, AGR %)
Figure 56 North America Ophthalmic Drugs Market Share Forecast by Type, 2024 & 2034 (%)
Figure 57 North America Ophthalmic Drugs Market Forecast by Distribution Channel, 2024-2034 (US$ Billion
Figure 58 North America Ophthalmic Drugs Market Share Forecast by Distribution Channel, 2024 & 2034 (%)
Figure 59 North America Ophthalmic Drugs Market Forecast by Indications, 2024-2034 (US$ Billion, AGR %)
Figure 60 North America Ophthalmic Drugs Market Share Forecast by Indications, 2024 & 2034 (%)
Figure 61 North America Ophthalmic Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Billion, AGR %)
Figure 62 North America Ophthalmic Drugs Market Share Forecast by Route of Administration, 2024 & 2034 (%)
Figure 63 U.S. Ophthalmic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 64 Canada Ophthalmic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 65 Europe Ophthalmic Drugs Market Attractiveness Index
Figure 66 Europe Ophthalmic Drugs Market by Region, 2024, 2029 & 2034 (US$ Billion)
Figure 67 Europe Ophthalmic Drugs Market Forecast by Country, 2024-2034 (US$ Billion, AGR %)
Figure 68 Europe Ophthalmic Drugs Market Share Forecast by Country, 2024 & 2034 (%)
Figure 69 Europe Ophthalmic Drugs Market Forecast by Type, 2024-2034 (US$ Billion, AGR %)
Figure 70 Europe Ophthalmic Drugs Market Share Forecast by Type, 2024 & 2034 (%)
Figure 71 Europe Ophthalmic Drugs Market Forecast by Distribution Channel, 2024-2034 (US$ Billion
Figure 72 Europe Ophthalmic Drugs Market Share Forecast by Distribution Channel, 2024 & 2034 (%)
Figure 73 Europe Ophthalmic Drugs Market Forecast by Indications, 2024-2034 (US$ Billion, AGR %)
Figure 74 Europe Ophthalmic Drugs Market Share Forecast by Indications, 2024 & 2034 (%)
Figure 75 Europe Ophthalmic Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Billion, AGR %)
Figure 76 Europe Ophthalmic Drugs Market Share Forecast by Route of Administration, 2024 & 2034 (%)
Figure 77 Germany Ophthalmic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 78 France Ophthalmic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 79 U.K. Ophthalmic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 80 Italy Ophthalmic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 81 Spain Ophthalmic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 82 Netherlands Ophthalmic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 83 Switzerland Ophthalmic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 84 Rest of Europe Ophthalmic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 85 Asia Pacific Ophthalmic Drugs Market Attractiveness Index
Figure 86 Asia Pacific Ophthalmic Drugs Market by Region, 2024, 2029 & 2034 (US$ Billion)
Figure 87 Asia Pacific Ophthalmic Drugs Market Forecast by Country, 2024-2034 (US$ Billion, AGR %)
Figure 88 Asia Pacific Ophthalmic Drugs Market Share Forecast by Country, 2024 & 2034 (%)
Figure 89 Asia Pacific Ophthalmic Drugs Market Forecast by Type, 2024-2034 (US$ Billion, AGR %)
Figure 90 Asia Pacific Ophthalmic Drugs Market Share Forecast by Type, 2024 & 2034 (%)
Figure 91 Asia Pacific Ophthalmic Drugs Market Forecast by Distribution Channel, 2024-2034 (US$ Billion
Figure 92 Asia Pacific Ophthalmic Drugs Market Share Forecast by Distribution Channel, 2024 & 2034 (%)
Figure 93 Asia Pacific Ophthalmic Drugs Market Forecast by Indications, 2024-2034 (US$ Billion, AGR %)
Figure 94 Asia Pacific Ophthalmic Drugs Market Share Forecast by Indications, 2024 & 2034 (%)
Figure 95 Asia Pacific Ophthalmic Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Billion, AGR %)
Figure 96 Asia Pacific Ophthalmic Drugs Market Share Forecast by Route of Administration, 2024 & 2034 (%)
Figure 97 Japan Ophthalmic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 98 China Ophthalmic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 99 India Ophthalmic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 100 Australia Ophthalmic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 101 South Korea Ophthalmic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 102 Malaysia Ophthalmic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 103 Singapore Ophthalmic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 104 Rest of Asia Pacific Ophthalmic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 105 Latin America Ophthalmic Drugs Market Attractiveness Index
Figure 106 Latin America Ophthalmic Drugs Market by Region, 2024, 2029 & 2034 (US$ Billion)
Figure 107 Latin America Ophthalmic Drugs Market Forecast by Country, 2024-2034 (US$ Billion, AGR %)
Figure 108 Latin America Ophthalmic Drugs Market Share Forecast by Country, 2024 & 2034 (%)
Figure 109 Latin America Ophthalmic Drugs Market Forecast by Type, 2024-2034 (US$ Billion, AGR %)
Figure 110 Latin America Ophthalmic Drugs Market Share Forecast by Type, 2024 & 2034 (%)
Figure 111 Latin America Ophthalmic Drugs Market Forecast by Distribution Channel, 2024-2034 (US$ Billion, AGR %)
Figure 112 Latin America Ophthalmic Drugs Market Share Forecast by Distribution Channel, 2024 & 2034 (%)
Figure 113 Latin America Ophthalmic Drugs Market Forecast by Indications, 2024-2034 (US$ Billion, AGR %)
Figure 114 Latin America Ophthalmic Drugs Market Share Forecast by Indications, 2024 & 2034 (%)
Figure 115 Latin America Ophthalmic Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Billion, AGR %)
Figure 116 Latin America Ophthalmic Drugs Market Share Forecast by Route of Administration, 2024 & 2034 (%
Figure 117 Brazil Ophthalmic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 118 Argentina Ophthalmic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 119 Mexico Ophthalmic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 120 Chile Ophthalmic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 121 Rest of Latin America Ophthalmic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 122 MEA Ophthalmic Drugs Market Attractiveness Index
Figure 123 MEA Ophthalmic Drugs Market by Region, 2024, 2029 & 2034 (US$ Billion)
Figure 124 MEA Ophthalmic Drugs Market Forecast by Country, 2024-2034 (US$ Billion, AGR %)
Figure 125 MEA Ophthalmic Drugs Market Share Forecast by Country, 2024 & 2034 (%)
Figure 126 MEA Ophthalmic Drugs Market Forecast by Type, 2024-2034 (US$ Billion, AGR %)
Figure 127 MEA Ophthalmic Drugs Market Share Forecast by Type, 2024 & 2034 (%)
Figure 128 MEA Ophthalmic Drugs Market Forecast by Distribution Channel, 2024-2034 (US$ Billion, AGR %)
Figure 129 MEA Ophthalmic Drugs Market Share Forecast by Distribution Channel, 2024 & 2034 (%)
Figure 130 MEA Ophthalmic Drugs Market Forecast by Indications, 2024-2034 (US$ Billion, AGR %)
Figure 131 MEA Ophthalmic Drugs Market Share Forecast by Indications, 2024 & 2034 (%)
Figure 132 MEA Ophthalmic Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Billion, AGR %)
Figure 133 MEA Ophthalmic Drugs Market Share Forecast by Route of Administration, 2024 & 2034 (%
Figure 134 GCC Ophthalmic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 135 South Africa Ophthalmic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 136 Rest of MEA Ophthalmic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 137 Ophthalmic Drugs Market: Company Share Analysis, 2023
Figure 138 Novartis AG: Net Revenue, 2018-2022 (US$ Million, AGR %)
Figure 139 Novartis AG: Regional Market Shares, 2022
Figure 140 Novartis AG: R&D Expense, 2018-2022 (US$ Million, AGR %)
Figure 141 Bayer AG: Net Revenue, 2018-2022 (US$ Million, AGR %)
Figure 142 Bayer AG: Regional Market Shares, 2022
Figure 143 Bayer AG: R&D Expense, 2018-2022 (US$ Million, AGR %)
Figure 144 Pfizer Inc.: Annual Revenue, 2018-2022 (US$ Million, AGR %)
Figure 145 Pfizer Inc.: Regional Market Shares, 2022
Figure 146 Pfizer Inc.: R&D Expense, 2018-2022 (US$ Million, AGR %)
Figure 147 Bausch & Lomb Incorporated: Annual Revenue, 2018-2022 (US$ Million, AGR %)
Figure 148 Bausch & Lomb Incorporated: R&D Expense, 2018-2022 (US$ Million, AGR %)
Figure 149 Santen Pharmaceutical Co., Ltd.: Annual Revenue, 2018-2022 (US$ Million, AGR %)
Figure 150 Santen Pharmaceutical Co., Ltd.: R&D Expense, 2018-2022 (US$ Million, AGR %)
Figure 151 Johnson & Johnson Services Inc.: Annual Revenue, 2018-2022 (US$ Million, AGR %)
Figure 152 Johnson & Johnson Private Limited: Regional Market Shares, 2022
Figure 153 Johnson & Johnson Private Limited: R&D Expense, 2018-2022 (US$ Million, AGR %)
Figure 154 Regeneron Pharmaceuticals Inc.: Annual Revenue, 2018-2022 (US$ Million, AGR %)
Figure 155 Regeneron Pharmaceuticals Inc: R&D Expense, 2018-2022 (US$ Million, AGR %)
Figure 156 AbbVie Inc.: Annual Revenue, 2018-2022 (US$ Million, AGR %)
Figure 157 AbbVie Inc.: Regional Market Shares, 2022
Figure 158 AbbVie Inc.: R&D Expense, 2018-2022 (US$ Million, AGR %)
Figure 159 F. Hoffmann-La Roche Ltd: Annual Revenue, 2018-2022 (US$ Million, AGR %)
Figure 160 F. Hoffmann-La Roche Ltd.: Regional Market Shares, 2022
Figure 161 F. Hoffmann-La Roche Ltd: R&D Expense, 2018-2022 (US$ Million, AGR %)
Figure 162 Teva Pharmaceutical Industries Ltd.: Annual Revenue, 2018-2022 (US$ Million, AGR%)
Figure 163 Teva Pharmaceutical Industries Ltd: Regional Market Shares, 2022
Figure 164 Teva Pharmaceutical Industries Ltd.: R&D Expense, 2018-2022 (US$ Million, AGR %)
Figure 165 Apellis Pharmaceuticals: Annual Revenue, 2018-2022 (US$ Million, AGR %)
Figure 166 Apellis Pharmaceuticals: R&D Expense, 2018-2022 (US$ Million, AGR %)
Figure 167 Alimera Sciences: Annual Revenue, 2018-2022 (US$ Million, AGR %)
Figure 168 Alimera Sciences: R&D Expense, 2018-2022 (US$ Million, AGR %)
List of Companies Profiled in the report
AbbVie Inc.
Alimera Sciences
Apellis Pharmaceuticals
Bausch & Lomb Incorporated
Bayer AG
Breye Therapeutics ApS
EyeBio
F. Hoffmann-La Roche Ltd.
Johnson & Johnson Services Inc.
Novaliq GmbH
Novartis AG
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Santen Pharmaceutical Co., Ltd.
SpliceBio
Teva Pharmaceutical Industries Ltd.
List of Other Companies Mentioned in the report
Akorn Operating Company LLC
Alkem Laboratories
Astellas Pharma Inc.
ATHOS KG
Bioeq GmbH
BioNanoSim
Chugai Pharmaceutical Co., Ltd.
ENTOD Pharmaceuticals
EyePoint Pharmaceuticals, Inc.
Formosa Pharmaceuticals, Inc.
Formycon AG
Iveric Bio, Inc.
Mylan Pharmaceuticals Inc.
NovaBay Pharmaceuticals Inc.
Oculis Holding AG
OcuMension Therapeutics
RAFARM
Senju Pharmaceutical Co., Ltd.
Taro Pharmaceutical Industries
Thea Pharma Inc.
UBE Corporation
Visus Therapeutics, Inc.
Zhaoke Ophthalmology Limited
List of Associations Mentioned in the Report
Centers for Disease Control and Prevention (CDC)
Drugs Controller General of India (DCGI)
European Medicines Agency (EMA)
Global Alliances and External Research (GAER)
Institute of Molecular and Clinical Ophthalmology Basel (IOB)
International Diabetes Federation (IDF)
Ministry of Health, Labour and Welfare (MHLW)
National Health Service (NHS)
National Medical Products Administration (NMPA)
Singapore Eye Research Institute (SERI)
U.S. Food and Drug Administration (FDA)
UCL Institute of Ophthalmology (IoO)
UK Medicines & Healthcare Regulatory Agency (MHRA)
World Health Organization (WHO)
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
